Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
UBS
Federal Trade Commission
Deloitte
Harvard Business School
Johnson and Johnson
Cipla
US Department of Justice
McKinsey

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,915,275

« Back to Dashboard

Which drugs does patent 7,915,275 protect, and when does it expire?

Patent 7,915,275 protects XIFAXAN and is included in one NDA.

This patent has eighty-two patent family members in thirty-six countries.
Summary for Patent: 7,915,275
Title:Use of polymorphic forms of rifaximin for medical preparations
Abstract: The present invention relates to Rifaximin polymorphic forms .alpha., .beta. and .gamma., to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.
Inventor(s): Viscomi; Giuseppe C. (Bologna, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Bologna, IT), Barbanti; Miriam (Bologna, IT), Calanni; Fiorella (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:11/873,841
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Formulation;

Drugs Protected by US Patent 7,915,275

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. ➤ Try a Free Trial
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,915,275

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI03A2144Nov 7, 2003

Non-Orange Book US Patents Family Members for Patent 7,915,275

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,906,542 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Try a Free Trial
8,158,644 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Try a Free Trial
8,158,781 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Try a Free Trial
7,045,620 Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,915,275

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 86384 ➤ Try a Free Trial
Taiwan I285107 ➤ Try a Free Trial
Taiwan 200515913 ➤ Try a Free Trial
Tunisia SN06069 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Daiichi Sankyo
UBS
Deloitte
McKesson
Fuji
Dow
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.